adamantane has been researched along with Disease Exacerbation in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| De, L; Yong, Z; Yuan, T | 1 |
| Xu, Y; Yang, W; Zhang, B | 1 |
| Chen, H; Gong, X; Hu, N; Li, F; Li, J; Li, Q; Li, Y; Qing, L; Wang, J; Yang, J; Yin, S; Zhu, S | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Araki, S | 1 |
| Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L | 1 |
| Keller, SN; Knudsen, KE; Schiewer, MJ; Schrecengost, RS; Smith, CD | 1 |
| Akhtar, M; Khan, S; Najmi, AK; Panda, BP | 1 |
| Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A | 1 |
| Bode, BW | 1 |
| Cefalu, WT | 1 |
| Fonseca, VA | 1 |
| Bianchi, R; Burkey, B; Cavaletti, G; Cervellini, I; Ghezzi, P; Lauria, G; Oggioni, N; Porretta-Serapiglia, C | 1 |
| Bergonzini, V; Bot, M; Costa, S; Freise, H; Maines, L; Nofer, JR; Poti, F; Robenek, H; Simoni, M; Varga, G | 1 |
| Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V | 1 |
| Akhtar, M; Imran, M; Khan, S; Najmi, AK; Pillai, KK | 1 |
| Bakris, GL; Flynn, C | 1 |
| Hammock, BD; Imig, JD; Kim, IH; Luria, A; Mitchell, BC; Newman, JW; Olearczyk, JJ; Quigley, JE; Yamamoto, T | 1 |
9 review(s) available for adamantane and Disease Exacerbation
| Article | Year |
|---|---|
ROS-responsive probes for low-background optical imaging: a review.
Topics: Acoustics; Adamantane; Animals; Disease Progression; Fluorescent Dyes; Humans; Luminescence; Luminol; Mice; Neoplasms; Optical Imaging; Photochemistry; Photosensitizing Agents; Reactive Oxygen Species; Ultrasonic Therapy; Ultrasonics | 2021 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
[Diabetic nephropathy].
Topics: Adamantane; Aged; Aged, 80 and over; Aging; Albuminuria; Antihypertensive Agents; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Humans; Hypertension; Hypoglycemia; Hypoglycemic Agents; Kidney; Nitriles; Pyrrolidines; Renal Dialysis; Sulfonylurea Compounds; Vildagliptin | 2013 |
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2008 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
Topics: Adamantane; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drugs, Investigational; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Risk Assessment; Risk Reduction Behavior | 2011 |
Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Thrombosis; Vildagliptin | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
9 other study(ies) available for adamantane and Disease Exacerbation
| Article | Year |
|---|---|
ST1926 inhibits glioma progression through regulating mitochondrial complex II.
Topics: Adamantane; Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cinnamates; Disease Progression; Electron Transport Complex II; Energy Metabolism; Enzyme Inhibitors; Glioma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis.
Topics: Adamantane; ADAMTS4 Protein; ADAMTS5 Protein; Aggrecans; Chondrocytes; Collagen Type II; Dipeptides; Disease Progression; Enzyme Activation; Gene Expression Regulation, Enzymologic; Glycation End Products, Advanced; Humans; Matrix Metalloproteinases; NF-kappa B; NF-KappaB Inhibitor alpha; Osteoarthritis; p38 Mitogen-Activated Protein Kinases; Proteolysis; Reactive Oxygen Species | 2019 |
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2015 |
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
Topics: Adamantane; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyridines; Receptors, Androgen; Signal Transduction; Small-Conductance Calcium-Activated Potassium Channels; Xenograft Model Antitumor Assays | 2015 |
Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Progression; Drug Therapy, Combination; Fibrinogen; Hypoglycemic Agents; Male; Nitriles; Pioglitazone; Platelet Count; Pyrrolidines; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazolidinediones; Thrombosis; Vildagliptin | 2015 |
Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Topics: Adamantane; Animals; Behavior, Animal; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drinking; Eating; Glucagon-Like Peptide 1; Glucose Tolerance Test; Male; Neural Conduction; Nitriles; Pain Threshold; Peripheral Nervous System Diseases; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Vildagliptin | 2012 |
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
Topics: Adamantane; Animals; Atherosclerosis; Cell Adhesion Molecules; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Cytokines; Dendritic Cells; Disease Models, Animal; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Humans; Inflammation Mediators; Mice; Mice, Knockout; Phosphotransferases (Alcohol Group Acceptor); Proprotein Convertases; Pyridines; Receptors, LDL; Serine Endopeptidases; T-Lymphocytes | 2012 |
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Diseases; Hypoglycemic Agents; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Myofibrils; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors; Urea | 2012 |
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.
Topics: Adamantane; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin; Lauric Acids; Lipids; Male; NF-kappa B; Rats; Rats, Inbred Strains | 2009 |